Diagnosis and Evaluation | Treatment > Cerebral Edema

Abstract

Nitric oxide synthase expression and enzymatic activity in human brain tumors

Broholm H, Rubin I, Kruse A, Braendstrup O, Schmidt K, Skriver EB, Lauritzen M

Department of Neuropathology, Rigshospitalet, Copenhagen, Denmark. hbroholm@rh.dk

Nitric oxide (NO) is synthesized by NO synthases (NOS), existing in 3 isoforms. 
NO influences a great variety of vital functions including vascular tone and neurotransmission. 
Under conditions of excessive formation, NO emerges as an important mediator of neurotoxicity in a variety of disorders of the central nervous system (CNS). 
Inhibitors of NOS are available that may modify the activity of all isoforms, which may be of clinical relevance. 
The expression of the 3 NOS isoforms nNOS, iNOS and eNOS and NOS enzymatic activity was examined in 40 patients with primary CNS tumors (gliomas WHO grades I - IV and meningeomas WHO grades I - III) and in 13 patients with metastases from adenocarcinomas or malignant melanomas. 
A polyclonal antibody directed against nNOS and monoclonal antibodies directed against iNOS and eNOS were used for immunohistochemical staining. 
NOS enzymatic activity, measured by labeled arginine to citrulline conversion, was assessed in tissue specimens obtained from the same tumors. 
NOS data were compared with clinical variables and the degree of edema as judged from MR scanning. 
nNOS expression was increased in tumor cells of glial neoplasms and most pronounced in high-grade tumors, WHO grades III and IV, and in the carcinoma and melanoma metastases. 
Low-grade gliomas, WHO grades I and II and meningeomas expressed no or only little nNOS. 
iNOS was only expressed in a few tumors. 
eNOS was expressed sporadically in the tumor cells while the expression was increased in vascular endothelial cells in both the tumor itself and the peritumoral area of glial neoplasms, and in metastases. 
eNOS expression was sporadic in endothelial cells of meningeomas. 
NOS enzymatic activities were heterogeneous among tumor types (0 - 13.8 pmol/min/mg of protein) without correlation to the NOS expression found by immunohistochemical techniques. 
Likewise, NOS activity and expression was not correlated to the clinical scores or brain edema. 
In conclusion, nNOS expression may be a putative useful indicator of brain tumor differentiation and malignancy. 
The enhanced expression of eNOS in vascular endothelial cells of glial neoplasms and metastases raises the possibility that NO production in tumor endothelial cells may contribute to tumor blood flow regulation and possibly brain edema.

PMID: 14672505 [PubMed - in process]